Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Receivables: 2015-2025

Historic Receivables for Fortress Biotech (FBIO) over the last 10 years, with Sep 2025 value amounting to $18.0 million.

  • Fortress Biotech's Receivables rose 68.52% to $18.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.9 million, marking a year-over-year increase of 33.78%. This contributed to the annual value of $10.2 million for FY2024, which is 33.23% down from last year.
  • Latest data reveals that Fortress Biotech reported Receivables of $18.0 million as of Q3 2025, which was up 14.95% from $15.6 million recorded in Q2 2025.
  • Fortress Biotech's Receivables' 5-year high stood at $32.1 million during Q3 2021, with a 5-year trough of $8.0 million in Q3 2023.
  • Its 3-year average for Receivables is $14.4 million, with a median of $13.0 million in 2023.
  • Its Receivables has fluctuated over the past 5 years, first surged by 242.05% in 2021, then slumped by 72.00% in 2023.
  • Over the past 5 years, Fortress Biotech's Receivables (Quarterly) stood at $24.7 million in 2021, then climbed by 21.84% to $30.1 million in 2022, then crashed by 49.11% to $15.3 million in 2023, then plummeted by 33.23% to $10.2 million in 2024, then surged by 68.52% to $18.0 million in 2025.
  • Its Receivables was $18.0 million in Q3 2025, compared to $15.6 million in Q2 2025 and $18.0 million in Q1 2025.